Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on October 25, 2021. The registrant is an emerging growth company incorporated in Delaware with principal executive offices in Alameda, California. The report details a specific financing event occurring on the date of the report.
Key Financial Metrics and Debt
- Debt Facility Utilization: The company borrowed an additional $0.5 million under its 2019 Loan Agreement with Juvenescence Limited.
- Total Borrowed: This transaction brought the total amount borrowed under the 2019 Loan Agreement to the full $6.0 million credit facility limit.
- Repayment Date: The outstanding principal balance is due and payable on February 14, 2022.
- Additional Liquidity: The company retains $500,000 of available credit under a separate Secured Convertible Facility Agreement entered into in March 2020, subject to lender approval.
- Revenue and Profit: The filing text does not provide specific values for revenue, profit, cash flow, or margins.
Material Changes
The primary material change reported is the full utilization of the $6.0 million credit facility under the 2019 Loan Agreement. Prior to this $0.5 million drawdown, the facility was not fully utilized. No other material changes to financial condition or operations are detailed in this specific filing.
Outlook, Risks, and Contingencies
- Events of Default: The lender (Juvenescence) may declare the loan immediately due and payable if an Event of Default occurs. Defined events include failure to pay within 10 business days, failure to perform obligations, incurrence of other indebtedness exceeding specific thresholds ($100,000 or $25,000 depending on terms), insolvency, cessation of business, or material adverse changes in financial condition.
- Forward-Looking Statements: The company includes standard disclaimers that actual results may differ materially from anticipated results due to various risk factors detailed in periodic SEC reports.
- Contingencies: The ability to access the remaining $500,000 under the separate Secured Convertible Facility is contingent upon Juvenescence's approval.
Investor Verification Checklist
- Verify the company's ability to repay the $6.0 million principal by the February 14, 2022 deadline.
- Review the terms of the separate Secured Convertible Facility Agreement to understand conditions for accessing the remaining $500,000.
- Monitor for any "Events of Default" that could trigger immediate acceleration of the debt.
- Check subsequent filings for updates on the company's cash position and operational progress given the full utilization of the primary credit line.